Market Currents

• Tuesday, September 8, 2009

• 09:14 AM Shares of Osiris Therapeutics (OSIR) plunge 38% premarket after it says two late-stage trials testing its lead product to treat a rare condition that affects bone marrow transplant patients failed to demonstrate statistical benefit over a placebo. Comment!
• 09:00 AM Premarket gainers: CBY +42%. ORH +25%. HMY +9%. NG +8%. STM +7%. GFI +7%. LTXC +7%. SLT +6%. AUO +6%. NXG +6%. HL +6%. VICL +6%. LYG +6%. CCL +6%. STP +6%. ALV +6%. EGO +6%. NGD +5%. LVS +5%. PAL +5%. PHG +5%. AUG +5%. NOK +5%. MT +5%. MPEL +5%. BHP +5%. GE +5%. ING +4%. GBG +4%. YGE +4%. MU +4%. RMBS +4%. GSS +4%. FNM +4%. ALU +4%. JASO +4%. FCX +4%. NVAX +4%.
  Losers: OSIR -40%. KFT -5%. MCO -5%. AIG -4%. Comment!

• Friday, March 27, 2009

• 09:07 AM Premarket losers: OSIR -26%. MGM -13%. UBS -10%. ACN -10%. ING -9%. DHT -7%. AIG -7%. PWE -7%. STP -7%. AAUK -6%. SOL -6%. BHP -6%. C -6%. SAP -6%. Comment!

• Tuesday, February 17, 2009

• 09:57 AM President Obama expected to soon sign an order lifting the funding ban on stem-cell research funding, an analyst tells CNBC at a conference today. Some pop in stem-cell stocks. GERN -2.5%. STEM +13.2%. OSIR -1.1%. ASTM +10.7%. 1 Comment

• Wednesday, November 5, 2008

• 08:43 AM The first stem cell company to post a quarterly profit, Osiris Therapeutics (OSIR) may also be the only profitable one in its field for a long time to come. With shares up 33% this year, says one analyst, ''you've got Osiris and you've got everybody else.' 2 Comments